BluePrint Medicines KIT D816V BLU-SM-1101 Evalute the prevalence of the KIT D816V mutation i peripheral blood of patients with evidence of systemic mast cell activation

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Blueprint Medicines Corporation

Contributors

Lugar, Patricia Lynne Principal Investigator

Start/End

February 9, 2022 - February 14, 2024